Australian drug development company Kazia Therapeutics Limited (NASDAQ:KZIA) on Monday announced the sale of all intellectual property and trademark rights for Cantrixil to Swedish development company Vivesto AB (STO:VIVE) for USD1m.
This agreement provides Kazia with non-dilutive funding to support its proprietary, clinical-stage pipeline.
Vivesto previously licensed the global development and commercialisation rights for Cantrixil from Kazia in March 2021. Initially intended for ovarian cancer, Vivesto has shifted its focus to preclinical exploration of Cantrixil for haematological cancers.
Cantrixil is a legacy asset in Kazia's portfolio, featuring TRXE-002-01, a third-generation benzopyran SMETI inhibitor encapsulated in α-cyclodextrin.
IDEAYA Biosciences advances Phase 3 design for darovasertib in primary uveal melanoma
Scancell partners with NHS Cancer Vaccine Launch Pad to accelerate melanoma trial recruitment
Sichuan Kelun-Biotech reveals sacituzumab tirumotecan (sac-TMT) clinical studies results
Amgen's IMDELLTRA shows superior overall survival in small cell lung cancer trial
EDX Medical launches new testicular cancer detection test in UK
Oncolytics Biotech signs share purchase agreement with Alumni Capital
SciTech Development secures second FDA clearance for ST-001 in early-stage cancer trials
MaaT Pharma receives positive DSMB safety recommendation for Phase 2b trial of MaaT033